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Aims The aims of the study were, ﬁrst, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and,
second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies.
Methods
and results
The robust and speciﬁc association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/cor-
onary heart disease (CHD) risk, together with recent genetic ﬁndings, indicates that elevated Lp(a), like elevated LDL-
cholesterol, is causally related to premature CVD/CHD. The association is continuous without a threshold or depen-
dence on LDL- or non-HDL-cholesterol levels. Mechanistically, elevated Lp(a) levels may either induce a prothrom-
botic/anti-ﬁbrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no ﬁbrinolytic
activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both. We
advise that Lp(a) be measured once, using an isoform-insensitive assay, in subjects at intermediate or high CVD/
CHD risk with premature CVD, familial hypercholesterolaemia, a family history of premature CVD and/or elevated
Lp(a), recurrent CVD despite statin treatment, ≥3% 10-year risk of fatal CVD according to European guidelines, and/
or ≥10% 10-year risk of fatal + non-fatal CHD according to US guidelines. As a secondary priority after LDL-choles-
terol reduction, we recommend a desirable level for Lp(a) ,80th percentile (less than  50 mg/dL). Treatment
should primarily be niacin 1–3 g/day, as a meta-analysis of randomized, controlled intervention trials demonstrates
reduced CVD by niacin treatment. In extreme cases, LDL-apheresis is efﬁcacious in removing Lp(a).
Conclusion We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level
,50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.
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Lipoprotein(a) [Lp(a)] has been considered a cardiovascular risk
factor for many years.
1 Owing to incomplete scientiﬁc evidence,
screening for and treatment of high Lp(a) levels have to date
been performed principally by lipid specialists. However, during
the last few years, major advances have been achieved in under-
standing the causal role of elevated Lp(a) in premature cardiovas-
cular disease (CVD).
2–4 These new ﬁndings have prompted the
present critical appraisal of the evidence base in the form of a Con-
sensus Paper.
Lipoprotein(a) is a plasma lipoprotein consisting of a
cholesterol-rich LDL particle with one molecule of apolipoprotein
B100 and an additional protein, apolipoprotein(a), attached via a
disulfide bond (Figure 1).
1 Elevated Lp(a) levels can potentially
increase the risk of CVD (i) via prothrombotic/anti-ﬁbrinolytic
effects as apolipoprotein(a) possesses structural homology with
plasminogen and plasmin but has no ﬁbrinolytic activity and (ii)
via accelerated atherogenesis as a result of intimal deposition of
Lp(a) cholesterol, or both.
Typical distributions of Lp(a) in Caucasians are shown in Figure 2:
plasma levels of Lp(a) are similar in men and women and are
Figure 1 Lipoprotein(a) consists of an LDL-like particle to which apolipoprotein(a) is covalently linked. The LDL-like moiety is composed of a
central core of cholesteryl esters (CE) and triglycerides (TG) surrounded by phospholipids (PL), free cholesterol (FC), and a single molecule of
apolipoprotein B (apoB). Apolipoprotein(a) contains 10 different types of plasminogen kringle 4-like repeats as well as regions homologous to
the kringle 5 and protease (P) regions of plasminogen. The kringle 4 type 2 domain (42) is present in multiply repeated copies from 2 to .40
that differ in number between apolipoprotein(a) isoforms.
1 Apolipoprotein(a) is linked to apolipoprotein B100 by a single disulﬁde bond invol-
ving an unpaired cysteine residue in kringle 4 type 9. Modiﬁed from Koschinsky and Marcovina.
18
Figure 2 Typical distributions of lipoprotein(a) levels in the general population. These graphs are based on non-fasting fresh serum samples
from  3000 men and 3000 women from the Copenhagen General Population Study collected from 2003 through 2004.
2 Green colour indi-
cates levels below the 80th percentile, whereas red colour indicates levels above the 80th percentile.
Lipoprotein(a) as a cardiovascular risk factor 2845skewed in the population with a tail towards the highest levels.
Levels are lowest in non-Hispanic Caucasians (e.g. median:
12 mg/dL; inter-quartile range: 5–32),
5 Chinese (11, 4–22), and
Japanese (13, 5–26), slightly higher in Hispanics (19, 8–43), and
even higher levels in Blacks (39, 19–69).
1,5 It is signiﬁcant that
Lp(a) has been surrounded by controversy among clinicians for
more than 20 years, and the various conceptions and misconcep-
tions are summarized and explained in Supplementary material
online, Table S1.
The aim of the present Consensus Paper is to critically evaluate
the evidence base supporting the contention that Lp(a) constitutes
a signiﬁcant cardiovascular risk factor. On the basis of the evidence,
the Consensus Panel provides recommendations on whom to
screen, desirable levels, and ﬁnally, how to treat elevated Lp(a)
levels. This is the ﬁrst Consensus Statement on diagnosis, desirable
levels, and treatment of elevated Lp(a).
Epidemiology
Findings from earlier prospective studies suggest that the relation
between Lp(a) concentration and the risk of CVD may involve a
threshold and that the association may be more marked among
individuals with elevated LDL cholesterol.
6–8 Individual studies,
however, are rarely sufﬁciently powered to assess the shape of
the relation or to make precise estimates of relative risk within
subgroups of the study populations such as among individuals
with high rather than low LDL cholesterol levels.
An early meta-analysis of 18 prospective studies of general
populations that was published before 2000, which reported on
a pooled analysis of 4000 coronary heart disease (CHD) cases,
suggested that the combined relative risk of CHD for individuals
in the top vs. bottom thirds of baseline Lp(a) concentrations was
1.7 (95% CI: 1.4–1.9).
9 An updated meta-analysis of 31 prospective
studies, involving a total of 9870 CHD cases, suggested that the
corresponding combined risk was more modest (relative risk:
1.5; 1.3–1.8).
10 Subgroups deﬁned by other characteristics pre-
speciﬁed for investigation, notably study size, sample storage
characteristics, and Lp(a) assay isoform sensitivity, were not signiﬁ-
cantly different.
Although the evidence from literature-based meta-analyses of
prospective studies suggests the potential importance of Lp(a) in
CHD, it does not provide sufﬁcient detail to allow the assessment
of the relevance of this lipoprotein to CVD prevention and treat-
ment. For example, it is not possible to determine, from a
literature-based meta-analysis, whether Lp(a) is associated with
CHD throughout the concentration range (similar to blood
pressure and LDL cholesterol) or whether Lp(a) is particularly
atherothrombogenic in speciﬁc subgroups of individuals (such as
in those with high LDL cholesterol level). Re-analysis of individual
participant data from a comprehensive set of prospective epide-
miological studies (i.e. individual participant data meta-analysis)
can help overcome several of the limitations of individual studies
or literature-based meta-analyses of individual studies. However,
because some of the earlier studies had problems with the
correct measurement of Lp(a) in, for example, frozen samples,
the risk estimates reported below should be considered minimal
estimates.
The largest epidemiological study to date on Lp(a) assessed indi-
vidual records of 126 634 participants in 36 prospective studies.
3
Lipoprotein(a) concentration was weakly correlated with several
known risk factors: positively with total and non-HDL cholesterol,
apolipoprotein B100, and inversely with loge triglycerides. Lipopro-
tein(a) levels were 12% (95% CI: 8–16%) higher in women and
11% (4–17%) lower in people with diabetes. The regression
dilution ratio of loge Lp(a), adjusted for age and sex, was 0.87
which was considerably higher than that for total cholesterol
(0.65), thereby suggesting that Lp(a) levels are remarkably stable
over time.
Associations of Lp(a) with CHD risk were broadly continuous in
shape and curvilinear, with no evidence of a threshold (Figure 3).
3
Assuming a log-linear association, the relative risk for CHD per
3.5-fold (1 SD) higher Lp(a) level, adjusted for age and sex only,
was 1.16 and 1.13 (95% CI: 1.09–1.18) following further adjust-
ment for systolic blood pressure, smoking, history of diabetes,
and total cholesterol, suggesting that any association is only mini-
mally confounded by conventional risk factors (Figure 4). Impor-
tantly, Lp(a) levels may vary up to a 1000-fold between
individuals (Figure 2).
1 The relative risk for CHD did not vary sig-
niﬁcantly by sex, non-HDL- or HDL cholesterol, triglycerides,
blood pressure, diabetes, or body mass index; in accordance, a
recent prospective study found that the Lp(a)/CHD risk associ-
ation did not depend on levels of other CVD risk factors, including
LDL cholesterol levels.
11 There was no convincing evidence of
major variations in relative risk in studies using isoform-sensitive
vs. -insensitive assays.
3
In analyses adjusted for age and sex only, the association of elev-
ated Lp(a) levels with increased risk of ischaemic stroke was less
pronounced than that for CHD (Figure 3).
3 However, the relatively
weak association with ischaemic stroke may be due to heterogen-
eity of stroke aetiologies, that is, the association in atherothrombo-
tic stroke could be diluted by weaker or no association with other
stroke subtypes. Assuming a log-linear association with risk, the
age-and-sex-only-adjusted relative risk for ischaemic stroke was
1.11 per 3.5-fold higher than usual Lp(a) levels and was 1.10
(95% CI: 1.02–1.18) following further adjustment for traditional
risk factors (Figure 4). The adjusted relative risks per 3.5-fold
higher than usual Lp(a) levels was 1.06 (0.90–1.26) for haemorrha-
gic stroke, 1.01 (0.98–1.05) for nonvascular mortality, 1.00 (0.97–
1.04) for all cancer deaths, 1.03 (0.97–1.09) for smoking-related
cancer deaths, and 1.00 (0.95–1.06) for non-vascular deaths
other than cancer.
In summary, elevated Lp(a) levels associate robustly and speciﬁ-
cally with increased CVD risk. The association is continuous in
shape without a threshold and does not depend on high levels
of LDL or non-HDL cholesterol, or on the levels or presence of
other cardiovascular risk factors.
Genetics
PlasmalevelsofLp(a)aretoalargeextentgeneticallydeterminedvia
variationintheapolipoprotein(a)gene.
1Thismakestheapolipopro-
tein(a) gene ideal for use in a Mendelian randomization study,
12
examining whether lifelong, genetically elevated levels of plasma
Lp(a) cause CVD. By analogy, familial hypercholesterolaemia with
B.G. Nordestgaard et al. 2846mutations in the LDL receptor or apolipoprotein B genes have life-
long, genetically elevated LDL cholesterol levels and premature
CVD,
13,14 a fact that has helped establish that elevated LDL choles-
terol levels constitute a direct cause of atherosclerosis and CVD.
A Mendelian randomization study needs three pieces of data to
help provide evidence for a causal link between elevated plasma
Lp(a) levels and CVD.
12 First, elevated plasma Lp(a) levels should
be associated with increased CVD risk, as demonstrated in the
previous section on Lp(a) epidemiology. Secondly, genetic vari-
ation should exist in human populations that can explain a large
fraction of the variation in plasma Lp(a) levels: such genetic vari-
ation has been known for many years, most importantly the
kringle IV type 2 size polymorphism (Figure 1,4 2), resulting in a
variable number from 2 to .40 number of a 5.6 kb repeat
Figure 3 Risk ratios of coronary heart disease, ischaemic stroke and non-vascular death by quantiles of usual lipoprotein(a) levels. CI, con-
ﬁdence interval. Sizes of data markers are proportional to the inverse of the variance of the risk ratios. (A) Adjustment for age and sex only. (B)
Further adjustment for systolic blood pressure, smoking status, history of diabetes, body mass index, and total cholesterol. MI, myocardial infarc-
tion. Modiﬁed from The Emerging Risk Factors Collaboration.
3
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repeats in the apolipoprotein(a) gene, the higher the plasma
levels of Lp(a), which has also been demonstrated in the past.
1
Thirdly, such genetic variation should be linked directly with
CVD risk: previous smaller case–control studies (n , 2400)
have demonstrated an association of kringle IV type 2 genotype
[or the associated apolipoprotein(a) isoform size] with risk of
CVD, as reviewed previously.
1,2
On the basis of the Copenhagen City Heart Study (CCHS), the
Copenhagen General Population Study (CGPS), and the
Copenhagen Ischemic Heart Disease Study (CIHDS) with 40 000
individuals genotyped for the kringle IV type 2 size polymorphism
in the apolipoprotein(a) gene, a large Mendelian randomization
study was published in 2009.
2 In the CCHS, multifactorially
adjusted hazard ratios for myocardial infarction for elevated lipo-
protein(a) levels were 1.2 (95% CI: 0.9–1.6) for the 22nd–66th
percentile, 1.6 (1.1–2.2) for the 67th–89th percentile, 1.9 (1.2–
3.0) for the 90th–95th percentile, and 2.6 (1.6–4.1) for levels
.95th percentile, respectively, vs. levels ,22nd percentile
(trend P , 0.001; Figure 5).
2,11
Figure 4 Risk ratios for various vascular and non-vascular endpoints per 3.5-fold (i.e. 1 SD) higher than usual lipoprotein(a) levels adjusted for
cardiovascular risk factors. MI, myocardial infarction.
aSubtotals do not add to the total number of coronary heart disease outcomes because
some studies did not subdivide outcomes into coronary death and non-fatal MI. RR, relative risk; CI, conﬁdence interval. Modiﬁed from The
Emerging Risk Factors Collaboration.
3
Figure 5 Risk of myocardial infarction by levels of lipoprotein(a) in the general population. Hazard ratios (HRs) are adjusted for cardiovas-
cular risk factors (multivariable) or for these factors as well as kringle IV type 2 (KIV-2) genotype. P-values are test for trend of hazard ratios
where lipoprotein(a) groups with increasing levels were coded 1, 2, 3, 4, and 5. Values are from the 1991–94 examination of the Copenhagen
City Heart Study with up to 16 years of follow-up (n ¼ 7524). CI, conﬁdence interval. Modiﬁed from Kamstrup et al.
2
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alleles) ranged from 6 to 99 and explained 21 and 27% of all vari-
ation in plasma lipoprotein(a) levels in the CCHS and the CGPS,
respectively.
2 Mean lipoprotein(a) levels were 56, 31, 20, and
15 mg/dL for the ﬁrst, second, third, and fourth quartiles of
kringle IV type 2 repeats in the CCHS, respectively (trend P ,
0.001; Figure 6); corresponding values in the CGPS were 60, 34,
22, and 19 mg/dL (trend P , 0.001).
In the CCHS, multifactorially adjusted hazard ratios for myocar-
dial infarction were 1.5 (1.2–1.9), 1.3 (1.0–1.6), and 1.1 (0.9–1.4)
for individuals in the ﬁrst, second, and third vs. fourth quartile of
kringle IV type 2 repeats, respectively (trend P , 0.001;
Figure 7).
2 Corresponding odds ratios were 1.3 (1.1–1.5), 1.1
(0.9–1.3), and 0.9 (0.8–1.1) in the CGPS (trend P ¼ 0.005), and
1.4 (1.1–1.7), 1.2 (1.0–1.6), and 1.3 (1.0–1.6) in the CIHDS
(trend P ¼ 0.01). The signiﬁcant similar trend tests in three separ-
ate studies all point to increased CVD risk when the number of
kringles is low and thus plasma levels of Lp(a) elevated.
2
Later in 2009, a further key paper on this topic including 8000
CHD cases and 8000 controls was published.
4 On the basis of
genotyping for 49 000 single-nucleotide polymorphisms (SNPs)
in 2100 candidate genes for CVD, 2 SNPs in linkage disequilibrium
with the kringle IV type 2 size polymorphism in the apolipopro-
tein(a) gene showed the highest of any association with CHD.
These two SNPs combined were found in one in six people and
together explained 36% of the variation in plasma Lp(a) levels.
The odds ratios for CHD were 1.51 (95% CI: 1.38–1.66) for
one variant and 2.57 (1.80–3.67) for two or more variants. Con-
sistent with these observations, a 2007 study tested 12 000 puta-
tive functional SNPs in many different genes and found that only
one, in the apolipoprotein(a) gene, was consistently associated
with severe coronary atherosclerosis.
15 Elevated Lp(a) is also an
independent CVD risk factor in patients with familial
hypercholesterolaemia.
16
Taken together, the robust and speciﬁc epidemiological associ-
ation between elevated plasma Lp(a) levels and increased risk of
CVD,
3 together with the two recent Mendelian randomization
studies,
2,4 support the contention that elevated Lp(a) levels, like
elevated LDL, is causally related to premature development of
atherosclerosis and CVD (Table 1).
Metabolism
It is believed that plasma concentrations of Lp(a) are determined
chieﬂy by rates of hepatic synthesis of apolipoprotein(a): although
the site of formation of Lp(a) has not been deﬁnitively identiﬁed,
evidence suggests that apolipoprotein(a) adducts extracellularly
and covalently to apolipoprotein B100-containing lipoproteins,
predominantly LDL.
17,18 Apolipoprotein(a) genotype, which
determines both the synthetic rate and size of the apolipopro-
tein(a) moiety of Lp(a), alone accounts for 90% of plasma concen-
trations of Lp(a).
17,19,20 As hepatic secretion rates are lower
for large apolipoprotein(a) isoforms, and as most individuals are
heterozygous for two different isoforms, the smallest isoform
typically predominates in plasma. Lipoprotein(a) is thought to
be catabolized primarily by hepatic and renal pathways, but
these metabolic routes do not appear to govern plasma Lp(a)
levels.
Pathophysiological mechanisms
underlying the atherothrombotic
potential of lipoprotein(a)
After transfer from plasma into the arterial intima, Lp(a) may be
more avidly retained than LDL as it binds to the extracellular
matrix not only through apolipoprotein(a), but also via its apolipo-
protein B component,
21 thereby contributing cholesterol to the
expanding atherosclerotic plaque. In vitro, Lp(a) binds to several
extracellular matrix proteins including ﬁbrin
22 and defensins, a
family of 29–35 amino acid peptides that are released by neutro-
phils during inﬂammation and severe infection.
23 It is likely that
Figure 6 Mean lipoprotein(a) levels in the Copenhagen City Heart Study as a function of quartiles of apolipoprotein(a) KIV-2 repeats. P-value
is for the Cuzick non-parametric test for trend of mean lipoprotein(a) levels. Participants in the 1991–94 or 2001–03 examination were
included (n ¼ 9867). KIV-2, kringle IV type 2. Error bars indicate 95% conﬁdence intervals. Modiﬁed from Kamstrup et al.
2
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and the extracellular matrix.
Transgenic mice expressing a mutant form of apolipoprotein(a)
with greatly reduced ability to bind to ﬁbrin exhibited 20% less
atherosclerotic lesion area and less accumulation in the arterial
wall compared with transgenic mice expressing wild-type Lp(a).
24
In addition, Lp(a) seems to be retained at sites of mechanical
injury;
21 ﬁbrin deposition occurs preferentially at such sites.
Through its apolipoprotein(a) moiety, Lp(a) also interacts with
the b2-integrin Mac-1, thereby promoting the adhesion of mono-
cytes and their transendothelial migration.
25 In atherosclerotic cor-
onary arteries, Lp(a) was found to localize in close proximity to
Mac-1 on inﬁltrating mononuclear cells.
Lipoprotein(a) has also been shown to bind pro-
inﬂammatory-oxidized phospholipids
26 and is a preferential carrier
of oxidized phospholipids in human plasma. Lipoprotein(a) also con-
tains lipoprotein-associated phospholipase A2 (equally referred to as
Paf-acetylhydrolase), which may cleave oxidized fatty acids at the
sn-2 position in oxidized phospholipids to yield short chain fatty
acids and lysolecithin.
27
Apolipoprotein(a), a homologue of the ﬁbrinolytic proenzyme
plasminogen, impairs ﬁbrinolysis.
28 Indeed, Lp(a)/apolipoprotein(a)
can competitively inhibit tissue-type plasminogen activator-mediated
plasminogen activation on ﬁbrin surfaces, although the mechanism of
inhibition by apolipoprotein(a) remains controversial. Essential to
ﬁbrinclotlysisare anumberofplasmin-dependent,positive feedback
reactions that enhance the efﬁciency of plasminogen activation,
including the plasmin-mediated conversion of Glu-plasminogen to
Lys-plasminogen. It has been observed that the apolipoprotein(a)
component of Lp(a) inhibits the key positive feedback step involving
conversion of plasmin-mediated Glu-plasminogen to Lys-
plasminogen.
29 Lipoprotein(a) may also enhance coagulation by inhi-
biting the function of tissue factor pathway inhibitor.
30
Finally, small isoforms of apolipoprotein(a) have been observed
to possess elevated potency in inhibiting ﬁbrinolysis and thereby
promoting thrombosis.
31 Indeed, a recent meta-analysis
Figure 7 Risk of myocardial infarction by quartiles of apolipoprotein(a) KIV-2 repeats in the Copenhagen City Heart Study (CCHS), the
Copenhagen General Population Study (CGPS), and the Copenhagen Ischemic Heart Disease Study (CIHDS). P-values are test for trend of
risk estimates [hazard ratios (HRs) or odds ratios (ORs)] where kringle IV type 2 (KIV-2) groups with decreasing numbers of KIV-2 repeats
were coded 1, 2, 3, and 4. CI, conﬁdence interval (shown as error bars). Modiﬁed from Kamstrup et al.
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mic stroke in subjects with small apolipoprotein(a) phenotypes.
32
Furthermore, prospective ﬁndings in the Bruneck study have
revealed a signiﬁcant association speciﬁcally between small apoli-
poprotein(a) phenotypes and advanced atherosclerotic disease
involving a component of plaque thrombosis.
33 These data
suggest that the determination of apolipoprotein(a) phenotype/
genotype may provide clinicians with additional information by
which to evaluate Lp(a)/apolipoprotein(a)-associated athero-
thrombotic risk.
Insummary,elevated Lp(a)levelsmaypromote atherosclerosisvia
Lp(a)-derived cholesterol entrapment in the intima, via inﬂammatory
cellrecruitment,and/orviathebindingofpro-inﬂammatory-oxidized
phospholipids. The prothrombotic, anti-ﬁbrinolytic actions of apoli-
poprotein(a) are expressed on the one hand as inhibition of ﬁbrino-
lysis with enhancement of clot stabilization and on the other as
enhanced coagulation via the inhibition of tissue factor pathway
inhibitor.
Measurement
Several types of Lp(a) assays are currently available, some com-
mercially; prominent among them are sandwich enzyme-linked
immunosorbent assays (ELISAs), non-competitive ELISAs, latex
immunoassays, immunonephelometric assays, and immunoturbido-
metric and ﬂuorescence assays.
19 In order for clinical laboratories
to provide clinicians with Lp(a) values which allow correct cardio-
vascular risk evaluation when Lp(a) is included in the estimate, the
following elements in standardization between Lp(a) assays are
critical.
(i) Inclusion of antibodies in assay kits whose immunoreactivity
with Lp(a) is apolipoprotein(a) isoform-insensitive and fully
characterized, and for which there is minor variation
between batches over time. In this regard, immunosorbent
assays are of considerable interest, as they allow the use of
polyclonal antibodies [anti-apolipoprotein(a) capture; anti-
apolipoprotein B100] and are isoform-insensitive.
19,28
(ii) Availability of a robust secondary reference Lp(a) preparation
at an international level, which has received approval by
organizations such as the International Federation of Clinical
Chemistry and the World Health Organisation.
(iii) The widespread use of methodologies which are robust,
highly reproducible with inter- and intra-coefﬁcient of vari-
ations ,10%, economically priced, and accurate.
(iv) A common resolve, based on the uniformity and widespread
availability of an approved and standardized Lp(a) assay, to
express Lp(a) concentrations as total Lp(a) protein; point
(ii) above is critical to this goal,
(v) Standardization of procedures for blood collection, plasma, or
serum isolation with a preferential use of fresh samples.
34
(vi) Ranges and percentiles for Lp(a) protein levels established for
individual ethnicities given present knowledge of race-
dependent variation in Lp(a),
1,5 ultimately leading to race-
speciﬁc estimates of risk thresholds.
These factors will contribute signiﬁcantly not only to the reliable
diagnosis and classiﬁcation of subjects presenting with high
.................................................................................
Table 2 Desirable levels for low-density lipoprotein
cholesterol and lipoprotein(a) levels in the fasting or
non-fasting state
Patients with
CVD and/or
diabetes
Other patients
and individuals
Highest level of
evidence for
treatment
LDL
cholesterol
,2 mmol/L
a
(,77 mg/dL)
,3 mmol/L
a
(,116 mg/dL)
Ia: meta-analysis
of randomized,
controlled
trials of statin
treatment
Lp(a) ,80th
percentile
(, 50
mg/dL
b)
,80th percentile
(, 50 mg/
dL
b)
Ia: meta-analysis
of randomised,
controlled
trials of niacin
treatment
c
aAccording to the 2007 European guidelines.
35
bThe 80th percentile roughly corresponds to 50 mg/dL in Caucasians (Figure 2).
cThe evidence is for the effect of niacin treatment, not speciﬁcally for Lp(a)
lowering.
...............................................................................................................................................................................
Table 1 Comparison of evidence supporting the contention that elevated low-density lipoprotein cholesterol and
elevated lipoprotein(a) each cause cardiovascular disease
Elevated LDL cholesterol Elevated Lp(a)
Human epidemiology Direct association in numerous studies Direct association in numerous studies
Human genetic
studies
Direct association in numerous studies, e.g. familial
hypercholesterolaemia
Direct association in numerous studies, e.g. for kringle IV type 2
polymorphism
Mechanistic studies Mechanism clearly demonstrated: LDL accumulate in intima and
cause atherosclerosis
Mechanism similar to that for LDL cholesterol and/or
prothrombotic/anti-ﬁbrinolytic effects
Animal models Proatherogenic effect in numerous studies Proatherogenic effect in numerous studies
Human intervention
trials
Statin trials gave ﬁnal proof of causality Niacin trials are favourable
Interpretation in
2010
Causality Probably causal
Lipoprotein(a) as a cardiovascular risk factor 2851atherothrombotic risk due to elevation of Lp(a), but also to the
success of multicentre clinical trials designed to evaluate pharma-
cotherapeutic agents targeted to concomitantly reduce elevated
Lp(a) levels and CVD risk.
Whom to screen
We suggest that Lp(a) should be measured once in all subjects at
intermediate or high risk of CVD/CHD who present with:
(i) premature CVD,
(ii) familial hypercholesterolaemia,
(iii) a family history of premature CVD and/or elevated Lp(a),
(iv) recurrent CVD despite statin treatment,
(v) ≥3% 10-year risk of fatal CVD according to the European
guidelines,
35 and
(vi) ≥10% 10-year risk of fatal and/or non-fatal CHD according to
the US guidelines
36
Repeat measurement is only necessary if treatment for high Lp(a)
levels is initiated in order to evaluate therapeutic response.
Desirable levels
Scientiﬁc and clinical evidence favouring an interpretation of caus-
ality between elevated levels of a lipoprotein and increased CVD
risk constitutes a pre-requisite for selection of desirable levels.
For an interpretation of causality, ﬁve types of evidence should
each favour causality and all three types of human evidence (epide-
miology, genetics, and intervention trials) must concur (Table 1).
37
For elevated LDL cholesterol levels, all ﬁve criteria are well docu-
mented and the consensus is causality. On the basis of the same
criteria, elevated Lp(a) levels probably are also causally related
to increased CVD risk (Table 1).
Recommendations proposing desirable levels should preferably
be based on evidence from a meta-analysis of randomized, con-
trolled intervention trials documenting beneﬁt of treatment
(level Ia evidence). Desirable levels for LDL cholesterol levels
are based on such evidence from statin trials (Table 2).
35,36 For
Lp(a), the evidence is less clear; however, a meta-analysis of
randomized, controlled intervention trials documenting beneﬁt
of niacin (¼nicotinic acid) treatment has recently been published
38
(see below).
For reduction of plasma Lp(a) as a secondary priority after
reduction in LDL and total cholesterol levels,
35,36 we recommend
a desirable level below the 80th percentile (less than  50 mg/dL;
Table 2). As for LDL reduction,
35,36 treatment of high Lp(a) levels
in persons without CVD/CHD or diabetes is recommended for
those with intermediate or high absolute risk of CVD/CHD (see
Graham et al.
35 and Grundy et al.
36 and Figure 3 in Kamstrup
et al.
11).
If statin treatment in a person with Lp(a) .50 mg/dl, but
without CVD or diabetes, reduces absolute risk for fatal CVD to
,3% or for fatal and/or non-fatal CHD to ,10%, there might
be no need for further treatment with niacin; however, in those
with premature CVD, familial hypercholesterolaemia, a family
history of premature CVD and elevated Lp(a), or recurrent CVD
despite statin treatment, niacin may still be justiﬁed despite
aggressive LDL cholesterol reduction with a statin.
Treatment
Studies using niacin alone or in combination with, for example,
statins have shown cardiovascular beneﬁt;
38–43 niacin reduces
Lp(a) levels by up to 30–40% in a dose-dependent manner and
in addition exerts other potential beneﬁcial effects by reducing
LDL cholesterol, total cholesterol, triglycerides, and remnant
cholesterol and by raising HDL cholesterol.
44 In a meta-analysis
including 11 randomized controlled trials with 2682 patients in
the active group and 3934 in the control group, niacin 1–3 g/day
reduced major coronary events by 25% (95% CI: 13–35%),
stroke by 26% (8–41%), and any cardiovascular event by 27%
(15–37%).
38
However, there have been no randomized, controlled interven-
tion trials with selective reduction in plasma lipoprotein(a) levels
aimed to reduce CVD: we urgently need trials demonstrating
that selective reduction of Lp(a) in those with Lp(a) above the
80th percentile will beneﬁt clinically with reduced CVD. Until
such trials are published, reduction in Lp(a) should mainly be
achieved using niacin, as the use of niacin for CVD risk reduction
as described above is evidence-based. However, in addition to
lowering Lp(a), niacin lowers LDL cholesterol, total cholesterol,
triglycerides, and remnant cholesterol and concomitantly increases
HDL cholesterol levels. Therefore, the favourable effects of
niacin on CVD cannot be ascribed solely to Lp(a) reduction.
Nevertheless, these studies clearly demonstrate that the use of
niacin for reduction in Lp(a) to the suggested desirable levels
(Table 2) is safe and in all likelihood beneﬁcial.
Compared with LDL, Lp(a) is relatively refractory to both life-
style and drug intervention.
20,45 The data on the effects of statins
and ﬁbrates on Lp(a) are limited and highly variable.
45,46 Overall,
statins have, however, been shown to consistently and modestly
decrease elevated Lp(a) in patients with heterozygous familial
hypercholesterolaemia. Other agents reported to decrease Lp(a)
to a minor degree (,10%) include aspirin, L-carnitine, ascorbic
acid combined with L-lysine, calcium antagonists, angiotensin-
converting enzyme inhibitors, androgens, oestrogen, and its
replacements (e.g. tibolone), anti-estrogens (e.g. tamoxifen), and
thyroxine replacement in hypothyroid subjects.
20,45,47
Larger studies of longer duration of Lp(a) lowering against back-
ground statin therapy in high-risk individuals including diabetics are
needed. In the FATS angiographic trial,
48 aggressive lowering of
LDL and apolipoprotein B abrogated the risk due to Lp(a) in patients
with established coronary disease. The ongoing AIM-HIGH (http
://clinicaltrials.gov/ct2/show/NCT00120289) and HPS2-THRIVE
(http://www.controlled-trials.com/ISRCTN29503772) trials will
further evaluate this notion, although the niacin employed in these
trials is not selective for Lp(a) lowering as noted above.
It is clear that more detailed studies of the metabolism of Lp(a)
are required to aid in the design and development of selective and
potent therapies for lowering Lp(a). Given the critical role of Lp(a)
synthesis in determining the plasma concentration of Lp(a), target-
ing either the synthesis of apolipoprotein(a) and/or the formation
of Lp(a) would appear worthwhile.
18,20 Antisense oligonucleotide
B.G. Nordestgaard et al. 2852and thyroid hormone analogue therapies directed at apolipopro-
tein(a) synthesis may hold particular promise for the future.
49,50
Finally, in young or middle-aged patients with evidence of pro-
gressive coronary disease and markedly elevated plasma Lp(a),
serious consideration should be given to instituting LDL apheresis
which removes Lp(a) efﬁcaciously;
51 however, this form of treat-
ment is prohibitively expensive and impractical for most patients
and most clinical centres.
Future needs in basic and clinical
research on lipoprotein(a) and
apolipoprotein(a)
The Consensus Panel is convinced that further international effort
is required in different ethnicities to assess the atherothrombotic
risk due to the Lp(a) particle on the one hand and to apolipopro-
tein(a) on the other. The potential contribution of Lp(a)-associated
phospholipase A2, and equally of Lp(a)-associated oxidized phos-
pholipids, to the pathophysiological mechanisms underlying such
elevated risk remains indeterminate. Both cutting-edge basic
research, rigorously designed prospective studies and intervention
trials of selective Lp(a) lowering agents are required to attain these
goals. Furthermore, it is entirely appropriate that Lp(a), as a causal,
independent risk factor, should be integrated into existing treat-
ment algorithms. Finally, randomized, controlled intervention
trials with selective reduction in plasma lipoprotein(a) levels to
reduce CVD in both primary and secondary prevention settings
are urgently needed in order to deﬁne more precisely who to
treat and to what targets.
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